Submit Manuscript  

Article Details


Anti-VEGF Therapy in Myopic CNV

[ Vol. 22 , Issue. 9 ]

Author(s):

Lisa Toto*, Luca Di Antonio, Olivia Costantino and Rodolfo Mastropasqua   Pages 1054 - 1063 ( 10 )

Abstract:


In this narrative-review, we report the most recent data from the literature of anti-vascular endothelial growth factor treatment for myopic choroidal neovascularization (mCNV). Myopic CNV is the most frequent sight-threatening complication of pathologic myopia. The natural course of mCNV can result in expanding macular atrophy and /or fibrosis, leading to irreversible visual loss after 5 years. Retinal multimodal imaging is mandatory for early diagnosis and monitoring of the disease during treatment. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended as the first-line treatment option for mCNV. Prompt treatment of active mCNV with intravitreal anti-VEGF therapy has been demonstrated to be effective in terms of visual outcome improvements reducing the occurrence of late-stage complications.

Keywords:

Myopic choroidal neovascularization, anti-vascular endothelial growth factor therapy, pathologic myopia, fundus fluorescein angiography, bevacizumab, ranibizumab, aflibercept.

Affiliation:

Ophthalmology Clinic, Department of Medicine and Science of Ageing, University G. D'Annunzio Chieti-Pescara, Chieti, via dei Vestini 31, 66100, Ophthalmology Clinic, Department of Medicine and Science of Ageing, University G. D'Annunzio Chieti-Pescara, Chieti, via dei Vestini 31, 66100, Ophthalmology Clinic, Department of Medicine and Science of Ageing, University G. D'Annunzio Chieti-Pescara, Chieti, via dei Vestini 31, 66100, Institute of Ophthalmology, University of Modena and Reggio Emilia, Modena

Graphical Abstract:



Read Full-Text article